Hasil Pencarian (1)
small molecule | CAS: 558447-26-0
Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist.[L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder cha…
Kategori:
AlkanesAminesButanes
+38
Target Protein:
C-X-C chemokine receptor type 4
Waktu ParuhThe mean (CV%) term…
Vol. DistribusiMavorixafor volume …
KlirensThe mean (CV%) appa…
Genetik
-